ARTICLE | Company News
Maxim submits NDA for Maxamine
July 19, 2000 7:00 AM UTC
MAXM submitted an NDA to the FDA for its Maxamine histamine dihydrochloride as an adjuvant to interleukin-2 (IL-2) to treat stage IV malignant melanoma. IL-2 is marketed for the indication under the n...